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Dear Sirs,
In terms of epidemiology, Guillain-Barré syndrome (GBS) 
accounts for 1–2 new cases/100.000 inhabitants per year 
[1, 2]. During the last two weeks, in coincidence with 
the descending slope of the pandemic peak in our region 
(Friuli Venezia-Giulia, Italy), we noted an unusual cluster 
of patients affected by GBS. The Neurology of the Udine 
University Hospital is the only Neurology Unit for the 
entire territory of the province, making unlikely the pos-
sibility of missing new cases, since this is the only facility 
for neurophysiological investigation and cerebrospinal fluid 
(CSF) examination in an area of 4,969.3 km2. Solicited by 
this observation and by a recent paper reporting the asso-
ciation of GBS with COVID-19 infection [3], we decided 
to re-examine the frequency of GBS cases during the 
March–April months of the last three years and to compare 
it with the admissions for GBS during the same months of 
the current year (up to April 16th).
After having the possibility to perform a quick test 
(Cellex™ q rapid test [4]) for the presence of IgM and IgG 
against SARS-CoV-2 nucleocapsid protein (N-protein), we 
tested the four patients still present in our ward and two 
more patients already discharged who accepted to come back 
to the hospital. Furthermore, we briefly described clinical, 
laboratory and neuro-physiological data of patients admit-
ted this year in Table 1. Data dealing with COVID-19 are 
reported in Table 2.
The total number of GBS in the March–April interval 
of the previous three years is four. In 2020, from March 1st 
to April 15th, we observed instead seven new cases diag-
nosed as GBS, in addition to a relapse in one more patient. 
This means 0.67 cases/month of observation (four cases in 
six months) in the previous three years, compared to 3.5 
cases/month (seven cases in two months) during the current 
year, which increases to 4 cases/month (eight cases in two 
months), if we consider also the patient with relapse. Consid-
ering a population of 535,516 inhabitants in the province of 
Udine (2017 census), the monthly incidence in March–April 
period of previous years was 0.12 new cases/100.000 inhab-
itants per month (in line with the epidemiological literature 
[1, 2]) versus 0.65 cases/100.000 inhabitants per month dur-
ing the ongoing pandemic. Accordingly, compared to years 
2017–2019, the increase of GBS cases in 2020 is 5.41-fold.
The suspicion that this striking difference could be due 
to the pandemic curve in our region is, therefore, legitimate. 
In fact, it is well known that GBS and related syndromes 
are often post-infectious (as for the influenza epidemics and 
more recently for Zika virus [5]), with an usual latency of 
10–14 days after infection [2]. However, in our series, only 
one patient (twice negative at swab test) had positive serol-
ogy and thorax CT scan. Despite the serologic and swab 
negativity of the others, we think that the association with 
the descending slope of SARS-CoV-2 infection should still 
be evaluated, since the specificity and sensitivity of these 
tests are not yet completely assessed and the exact slope of 
the humoral immune response curve to this new virus is still 
unknown. It could also be possible that asymptomatic or 
paucisymptomatic infections may not develop an antibody 
response sufficient enough to be detected, especially consid-
ering that the available test is only qualitative.
We wonder if similar clusters have been observed 
elsewhere.
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Table 1  Demographic, clinical, CSF and neurophysiological findings in the observed population with GBS
ID patient identification number, GBS Guillain-Barré syndrome, CSF cerebrospinal fluid, M male, F female, AMSAN acute motor-sensory axonal 
neuropathy, AIDP acute inflammatory demyelinating polyneuropathy, MFS Miller-Fisher syndrome, c.n. cranial nerve, r normal range for labo-
ratory, NA not available
a During patient’s first episode of AIDP, with onset on December 2019, CSF examination showed a protein content of 930 mg/L, with 0.8/µL 
cells. On the occasion of the clinical relapse, lumbar puncture was not performed
ID Age, Sex Previous 
infection 
symptoms






1 76, M No Tetraparesis
Dysarthria
Dysautonomia
27/02/2020 228 mg/L 0.6/µL AMSAN
2 70, M Diarrhea Paraparesis
Paraesthesia
Ataxia
07/02/2020 216 mg/L 0.6/µL AIDP




20/03/2020 933 mg/L 0/µL AIDP
4 59, M No Emifacial paresthesia
Facial weakness (VII c.n.)
Dysarthria (XII c.n.)
24/03/2020 701 mg/L 2.8/µL Altered blink reflex, demy-
elinating damage (MFS)






01/03/2020 1124 mg/L 0.4/µL AIDP
6 82, M Fever Asymmetric paraparesis 28/03/2020 827 mg/L 0.8/µL AIDP




01/04/2020 1928 mg/L 2.6/µL AIDP
8 59, F No Tetraparesis
Paraesthesia
11/02/2020 (relapse) NAa (relapse) NA (relapse) AIDP relapse




Swab test Thorax imaging sug-
gestive for COVID-
19













1 No 24/03/2020 negative Interstitial pneumo-
nia
NA NA Negative Multiplex 
 PCRb (CSF)
Negative serology 
for  Borreliac and 
TBE (CSF), WNV 
(serum)
Negative
2 Yes 24/03/2020 negative No Negative (blood) NA Negative serology for 
Borrelia and TBE 
(serum)
Negative
3 No 15/04/2020 negative No Negative (blood) Negative Negative Multiplex 
PCR (CSF)
Negative serology for 
Borrelia and TBE 
(CSF)
NA
4 No 27/03/2020 negative No Negative (blood) Negative Negative Multiplex 
PCR (CSF)
Negative serology for 
Borrelia and TBE 
(serum and CSF)
Negative
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ID patient identification number, CT computed tomography, PCR polymerase chain reaction, CSF cerebrospinal fluid, NA not available, CMV 
Cytomegalovirus, EBV Epstein-Barr virus, HSV-1 Herpes simplex virus 1, HSV-2 Herpes simplex virus 2, HHV-6 Human herpes virus 6, HPeV 
Human parechovirus, VZV Varicella-zoster virus, TBE Tick-borne encephalitis, WNV West-Nile virus
a We intend symptoms such as fever, cough, cold and diarrhea
b Mutliplex PCR: EBV, CMV, Enterovirus, HSV-1, HSV-2, HHV-6, HPeV, VZV
c Borrelia burgdorferi
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Swab test Thorax imaging sug-
gestive for COVID-
19













5 Yes 20/03/2020 negative No Negative (blood) NA Negative Multiplex 
PCR (CSF)
Negative
6 Yes 07/04/2020 negative No Negative (blood) Negative NA NA




Positive IgM and IgG
(blood and CSF)
Negative Negative PCR for 
influenza A and 
B viruses (nasal 
swab)
Negative serology for 
Borrelia and TBE 
(CSF)
Negative







NA NA NA GD1a + 
GT1b, 
anti-
sulfatide 
low 
titer + 
Table 2 Continued
